 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
14 News |  |
- | MEDI4166 / AstraZeneca
Journal: Engineering of a GLP-1 analogue peptide/anti-PCSK9 antibody fusion for type 2 diabetes treatment. (Pubmed Central) - Oct 24, 2019
MEDI4166 showed robust and sustained LDL-C lowering in cynomolgus monkeys and exhibited the anticipated GLP-1 effects in T2D mouse models. We believe MEDI4166 is a novel molecule combining long acting agonist peptide and neutralising antibody activities to deliver a unique pharmacology profile for the management of T2D.
- | MEDI4166 / AstraZeneca
Clinical, P1 data, Journal: Randomised, phase 1, dose-finding study of MEDI4166, a PCSK9 antibody and GLP-1 analogue fusion molecule, in overweight or obese patients with type 2 diabetes mellitus. (Pubmed Central) - Jun 26, 2019
P1
MEDI4166 was associated with an acceptable tolerability profile and significantly decreased LDL-cholesterol levels in a dose-dependent manner in overweight or obese patients with type 2 diabetes. However, there were no significant reductions in postprandial glucose levels at any dose of MEDI4166.
- ||| MEDI4166 / AstraZeneca
Trial completion, Enrollment change: A Phase 1, Single- and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MEDI4166 in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Jul 12, 2017
P1, N=103, Completed, Sponsor: MedImmune LLC
However, there were no significant reductions in postprandial glucose levels at any dose of MEDI4166. Active, not recruiting --> Completed | N=497 --> 103
- || MEDI4166 / AstraZeneca
Enrollment closed, Enrollment change: A Phase 1, Single- and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MEDI4166 in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Feb 15, 2017
P1, N=497, Active, not recruiting, Sponsor: MedImmune LLC
Active, not recruiting --> Completed | N=497 --> 103 Recruiting --> Active, not recruiting | N=100 --> 497
- || MEDI4166 / AstraZeneca
Phase classification, Trial primary completion date: A Phase 1, Single- and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MEDI4166 in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Dec 14, 2016
P1, N=100, Recruiting, Sponsor: MedImmune LLC
Recruiting --> Active, not recruiting | N=100 --> 497 Phase classification: P1/2 --> P1 | Trial primary completion date: Nov 2016 --> Mar 2017
- ||| MEDI4166 / AstraZeneca
Phase classification, Trial initiation date: A Phase 1, Single- and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MEDI4166 in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Apr 28, 2016
P1/2, N=124, Recruiting, Sponsor: MedImmune LLC
Phase classification: P1/2 --> P1 | Trial primary completion date: Nov 2016 --> Mar 2017 Phase classification: P1 --> P1/2 | Initiation date: Feb 2015 --> Oct 2015
- || MEDI4166 / AstraZeneca
Trial initiation date: A Phase 1, Single- and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MEDI4166 in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Mar 2, 2016
P1, N=124, Recruiting, Sponsor: MedImmune LLC
Phase classification: P1 --> P1/2 | Initiation date: Feb 2015 --> Oct 2015 Initiation date: Oct 2015 --> Feb 2015
- ||| MEDI4166 / AstraZeneca
Enrollment open: A Phase 1, Single- and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MEDI4166 in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Nov 9, 2015
P1, N=124, Recruiting, Sponsor: MedImmune LLC
Initiation date: Oct 2015 --> Feb 2015 Not yet recruiting --> Recruiting
- ||| MEDI4166 / AstraZeneca
New P1 trial: A Phase 1, Single- and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MEDI4166 in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Aug 17, 2015
P1, N=124, Not yet recruiting, Sponsor: MedImmune LLC